Comparisons versus I-O monotherapies ranged from $6119 per QALY (IPI) to $76,169 per QALY (NIVO) (Table 4).Table 3Total LYs, QALYs, and total costs in the cost-utility analysis of first-line therapies for advanced melanomaTreatmentLYsQALYsTreatment costs, US$aAdministrative costs, US$aDisease management costs, US$a,bToxicity costs, US$aSubsequent treatment costs, US$a,cTotal costs, US$aPrimary analysis: NMA, all-comers NIVO + IPI6.995.70230,69911,82327,66077,578121,708469,469 NIVO5.794.81168,56611,58214,65312,369194,412401,582 IPI3.332.74130,706157689593213306,886451,340 DAB + TRAM3.983.24191,755054246835199,184403,198 ENCO + BINI4.613.71214,9180543934,249210,613465,220 VEM + COBI3.192.54149,4940523931,188200,770386,690 PEMBRO4.833.99160,028744191006662231,166414,397Secondary analysis: NMA, BRAF-mutant subgroup NIVO + IPI7.416.04229,43311,67926,35376,750131,993476,208 NIVO5.664.67136,064934993939984227,173391,963 IPI3.332.74130,706157689593213306,886451,340 DAB + TRAM3.933.19175,426046196259200,075386,379 ENCO + BINI4.563.67194,0800479831,081211,454441,413 VEM + COBI3.142.50136,5760459528,558201,433371,162Secondary analysis: MAIC NIVO + IPI8.416.88223,96511,58529,23375,841128,942469,566 DAB + TRAM3.562.92209,769020,5967456169,920407,742 ENCO + BINI4.383.53266,916023,10641,350180,204511,577 VEM + COBI3.963.18173,365017,32535,820189,680416,189DAB + TRAM dabrafenib plus trametinib, ENCO + BINI encorafenib plus binimetinib, IPI ipilimumab, LYs life-years, MAIC matching-adjusted indirect comparison, NIVO nivolumab, NIVO + IPI nivolumab plus ipilimumab, NMA network meta-analysis, PEMBRO pembrolizumab, QALYs quality-adjusted life-years, US$ US dollars, VEM + COBI vemurafenib plus cobimetiniba2020 US$bIncludes pre-progression disease management costs onlycIncludes post-progression disease management costs and active subsequent systemic treatment costsTable 4Incremental results for NIVO + IPI in the cost-utility analysis of first-line therapies for advanced melanomaAnalysis/comparatorIncremental outcomes for NIVO + IPIQALYsCosts, US$aICUR, US$aPrimary analysis: NMA, all-comers NIVO0.8967,88676,169 IPI2.9618,1296119 DAB + TRAM2.4766,27126,876 ENCO + BINI2.0042492130 VEM + COBI3.1782,77926,139 PEMBRO1.7155,07232,183Secondary analysis: NMA, BRAF-mutant subgroup NIVO1.3784,24561,596 IPI3.3024,8687540 DAB + TRAM2.8489,82831,579 ENCO + BINI2.3734,79414,708 VEM + COBI3.54105,04629,662Secondary analysis: MAIC DAB + TRAM3.9661,82415,604 ENCO + BINI3.35−42,011Dominant VEM + COBI3.7053,37714,411DAB + TRAM dabrafenib plus trametinib, ENCO + BINI encorafenib plus binimetinib, ICUR incremental cost-utility ratio, IPI ipilimumab, NIVO nivolumab, NIVO + IPI nivolumab plus ipilimumab, MAIC matching-adjusted indirect comparison, NMA network meta-analysis, PEMBRO pembrolizumab, QALYs quality-adjusted life-years, US$ US dollars, VEM + COBI vemurafenib plus cobimetiniba2020 US$